Next Post

Pfizer COVID-19 pill did not meet main goal in infection prevention (NYSE:PFE)

Jeenah Moon/Getty Images NewsRelated Posts:Business News for April 4, 2022 Announcing topline data from a Phase 2/3 study for Paxlovid, Pfizer (NYSE:PFE) said on Friday that the COVID-19 antiviral did not meet the main goal in the trial designed to evaluate its effect in the prevention of infection. The recruitment […]
Pfizer Makes $1.95 Billion Deal With U.S. For Future COVID-19 Vaccine